<DOC>
	<DOCNO>NCT01522612</DOCNO>
	<brief_summary>OBJECTIVE : The principal objective trial evaluate whether addition cetuximab associate 5-fluorouracil elderly patient KRAS wild type advance colorectal cancer ( CRC ) prolongs Progression Free Survival , compare 5-fluorouracil alone .</brief_summary>
	<brief_title>Colorectal Cancer ( CRC ) Cetuximab Elderly Frail</brief_title>
	<detailed_description>The primary efficacy analysis perform Intention-to-treat population . The safety analyse perform Safety population . - Median PFS OS treatment arm 95 % CI , estimate Kaplan-Meier technique - Response rate treatment arm exact 95 % CI - IADL sum score , G8 sum score social situation treatment arm baseline timepoint assessment - QoL score EORTC QLQ-C30 QLQ-ELD14 module treatment arm baseline timepoint assessment - Safety data treatment arm Safety population . Worst toxicity grade cycle accord CTCAE criterion version 4.0 treatment arm . - Pharmaco-economics evaluation Summary propose Phase II trial characteristic : 1 . Total number randomize patient : 150 . 2 . Total number event phase II analysis primary endpoint : 110 . 3 . Total number patient screen phase II : 250 . 4 . Total number patient treat cetuximab Phase II study : 75 . 5 . Maximum study duration : 19 month . In present study , HRQoL important secondary endpoint . The objective HRQoL data collection Phase II trial ass impact addition cetuximab patient ' HRQoL treatment . The hypothesis difference patient ' HRQoL treatment arm treatment . The HRQoL domain ( EORTC QLQ-C30 module ) expect affected treatment ( extent arm ) Global health status , Fatigue , Pain Stool habit .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Pathologically confirm metastatic colorectal cancer Measurable disease accord RECIST V1.1 Histological local review analysis KRAS Age ≥ 80 ≥ 70 combination functional restriction define limitation least 2 8 IADL WHO performance status 0 , 1 2 Adequate bone marrow reserve , hepatic function &amp; renal function Normal 12 lead ECG without clinically significant abnormality Written inform consent randomization accord ICH/EU GCP , local , national international regulation Prior systemic chemotherapy metastatic disease Previous exposure EGFR VEGF/VEGFR target therapy Patients may receive chemotherapy adjuvant neoadjuvant setting ( CRC ) . The treatmentfree interval 6 month end ( neo ) adjuvant therapy Previous radiotherapy , either adjuvant setting treatment bone metastasis , allow provide measurable lesion outside radiation field Persistence clinically relevant treatmentrelated toxicity previous chemotherapy and/or radiotherapy ( adjuvant neoadjuvant setting ) Treatment investigational drug treatment another clinical trial within past four week start treatment concomitantly trial Known alcohol drug abuse Clinically significant cardiovascular disease Evidence uncontrolled medical comorbidities despite adequate treatment Patients suffer cerebrovascular accident transient ischemic attack within past 12 month History , within past 5 year , malignancy CRC Psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>KRAS Wild Type</keyword>
	<keyword>Frail Elderly</keyword>
	<keyword>QLQ-C30</keyword>
	<keyword>QLQ-ELD14</keyword>
	<keyword>CGA</keyword>
	<keyword>EGFR</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>5-FU</keyword>
</DOC>